Bibliography | Clinical Research Centre 023 TB Non Clinical
Tuberculosis (Non-Clinical)
1. Anonymous Tuberculosis and leprosy: potential novel drugs and vaccines
against Mycobacterium. A Symposium held at Universiti Malaysia Sabah, Kota
Kinabalu, Sabah, Malaysia, July 3-5, 2002. Proceedings. Tuberculosis (Edinb)
2004;84(1-2):1-130.
2. Abdulla JMA, Haris HH, Ibrahim P, et al. Susceptibility of Mycobacterium
tuberculosis
to
rifampicin
loaded
poly-(ethylene
oxide)blockmethoxydistearoylphosphatidylethanolamine. Malaysian Journal of
Pharmaceutical Sciences 2004;2(2):39-39
http://myais.fsktm.um.edu.my/6877/1/susceptibility_vol2_no2_(39)2004.PDF
3. Acosta A, Norazmi MN, Hernandez-Pando R, et al. The importance of animal
models in tuberculosis vaccine development. Malays J Med Sci 2011;18(4):512
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328939/pdf/mjms-18-4005.pdf
4. Ansari AW, Kamarulzaman A, Schmidt RE. Multifaceted Impact of Host C-C
Chemokine CCL2 in the Immuno-Pathogenesis of HIV-1/ Co-Infection. Front
Immunol 2013;4:312.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790230/pdf/fimmu-0400312.pdf
5. Atif M, Sulaiman SA, Shafie AA, et al. Tracing contacts of TB patients in
Malaysia: costs and practicality. Springerplus 2012;1:40-1801-1-40.
6. Calero R, Mirabal M, Bouza J, et al. In Silico identification of M. TB proteins
with diagnostic potential. BMC Immunol 2013;14 Suppl 1:S9-2172-14-S1-S9.
Epub 2013 Feb 25.
7. Elamin EI, Ibrahim MI, Sulaiman SA, et al. Cost of illness of tuberculosis in
Penang, Malaysia. Pharm World Sci 2008;30(3):281-286.
8. Nor NM, Musa M. Approaches towards the development of a vaccine against
tuberculosis: recombinant BCG and DNA vaccine. Tuberculosis (Edinb)
2004;84(1-2):102-109.
9. Ong CS, Ngeow YF, Yap SF, et al. Evaluation of PCR-RFLP analysis targeting
hsp65 and rpoB genes for the typing of mycobacterial isolates in Malaysia. J
Med Microbiol 2010;59(Pt 11):1311-1316.
10.Othman GQ, Ibrahim MI, Raja'a YA. Costs associated with tuberculosis
diagnosis and treatment in Yemen for patients and public health services.
East Mediterr Health J 2012;18(4):393-398.
11.Saifullah B, Hussein MZ, Hussein-Al-Ali SH, et al. Antituberculosis nanodelivery
system with controlled-release properties based on para-amino salicylate-zinc
aluminum-layered double-hydroxide nanocomposites. Drug Des Devel Ther
2013;7:1365-1375.
Page 1 of 2
12.Shankar EM, Vignesh R, Ellegard R, et al. HIV-Mycobacterium tuberculosis coinfection: A 'danger-couple model' of disease pathogenesis. Pathog Dis 2013;.
13.Suppian R, Zainuddin ZF, Norazmi MN. Cloning and expression of malaria and
tuberculosis epitopes in mycobacterium bovis bacille calmette-guerin. Malays
J Med Sci 2006;13(1):13-20
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347897/pdf/mjms-13-1013.pdf
Page 2 of 2
1. Anonymous Tuberculosis and leprosy: potential novel drugs and vaccines
against Mycobacterium. A Symposium held at Universiti Malaysia Sabah, Kota
Kinabalu, Sabah, Malaysia, July 3-5, 2002. Proceedings. Tuberculosis (Edinb)
2004;84(1-2):1-130.
2. Abdulla JMA, Haris HH, Ibrahim P, et al. Susceptibility of Mycobacterium
tuberculosis
to
rifampicin
loaded
poly-(ethylene
oxide)blockmethoxydistearoylphosphatidylethanolamine. Malaysian Journal of
Pharmaceutical Sciences 2004;2(2):39-39
http://myais.fsktm.um.edu.my/6877/1/susceptibility_vol2_no2_(39)2004.PDF
3. Acosta A, Norazmi MN, Hernandez-Pando R, et al. The importance of animal
models in tuberculosis vaccine development. Malays J Med Sci 2011;18(4):512
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328939/pdf/mjms-18-4005.pdf
4. Ansari AW, Kamarulzaman A, Schmidt RE. Multifaceted Impact of Host C-C
Chemokine CCL2 in the Immuno-Pathogenesis of HIV-1/ Co-Infection. Front
Immunol 2013;4:312.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790230/pdf/fimmu-0400312.pdf
5. Atif M, Sulaiman SA, Shafie AA, et al. Tracing contacts of TB patients in
Malaysia: costs and practicality. Springerplus 2012;1:40-1801-1-40.
6. Calero R, Mirabal M, Bouza J, et al. In Silico identification of M. TB proteins
with diagnostic potential. BMC Immunol 2013;14 Suppl 1:S9-2172-14-S1-S9.
Epub 2013 Feb 25.
7. Elamin EI, Ibrahim MI, Sulaiman SA, et al. Cost of illness of tuberculosis in
Penang, Malaysia. Pharm World Sci 2008;30(3):281-286.
8. Nor NM, Musa M. Approaches towards the development of a vaccine against
tuberculosis: recombinant BCG and DNA vaccine. Tuberculosis (Edinb)
2004;84(1-2):102-109.
9. Ong CS, Ngeow YF, Yap SF, et al. Evaluation of PCR-RFLP analysis targeting
hsp65 and rpoB genes for the typing of mycobacterial isolates in Malaysia. J
Med Microbiol 2010;59(Pt 11):1311-1316.
10.Othman GQ, Ibrahim MI, Raja'a YA. Costs associated with tuberculosis
diagnosis and treatment in Yemen for patients and public health services.
East Mediterr Health J 2012;18(4):393-398.
11.Saifullah B, Hussein MZ, Hussein-Al-Ali SH, et al. Antituberculosis nanodelivery
system with controlled-release properties based on para-amino salicylate-zinc
aluminum-layered double-hydroxide nanocomposites. Drug Des Devel Ther
2013;7:1365-1375.
Page 1 of 2
12.Shankar EM, Vignesh R, Ellegard R, et al. HIV-Mycobacterium tuberculosis coinfection: A 'danger-couple model' of disease pathogenesis. Pathog Dis 2013;.
13.Suppian R, Zainuddin ZF, Norazmi MN. Cloning and expression of malaria and
tuberculosis epitopes in mycobacterium bovis bacille calmette-guerin. Malays
J Med Sci 2006;13(1):13-20
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347897/pdf/mjms-13-1013.pdf
Page 2 of 2